多发性骨髓瘤是骨髓浆细胞恶性疾病,平均发病年龄为65岁。随着人口老龄化的加剧,多发性骨髓瘤已逐渐成为威胁老年人健康的主要疾病之一。复发耐药性多发性骨髓瘤患者缺乏有效的治疗方案,是目前该病的主要死亡原因。尽管治疗策略已从传统的化疗、自体造血干细胞移植演变为以沙利度胺与硼替佐米为代表的新型靶向药物治疗,多发性骨髓瘤的预后得到了显著的改善,但至今为止,多发性骨髓瘤仍是一种不 Multiple myeloma is a malignant disease of bone marrow plasma cells with an average age of onset of 65 years. As the population ages, multiple myeloma has gradually become one of the major diseases threatening the health of the elderly. The lack of an effective treatment regimen for patients with relapsed drug-resistant multiple myeloma is the major cause of death of the disease. Although the therapeutic strategy has evolved from traditional chemotherapy and autologous stem cell transplantation to new targeted drug therapy such as thalidomide and bortezomib, the prognosis of multiple myeloma has been significantly improved, but so far, multiple Sexual myeloma is still not a kind